We are honored to invite Dr. Mark Leick to introduce a novel approach that leverages CAR-T cells for the targeted delivery of anti-VEGF therapeutics. Join us to explore how these engineered CAR-T cells (CARVEGF) function as "Trojan horses" to unleash a dual-pronged attack: directly targeting tumor cells while simultaneously delivering localized VEGF blockade to disrupt tumor angiogenesis. This strategy enhances CAR-T cell activity and proliferation, demonstrating significant in vivo potency in challenging solid tumor models.
During this webinar, we will discuss the following key points:
- Activated CAR-T cells upregulate VEGF pathway members
- CARVEGF have enhanced in vitro anti-tumor activity and proliferation
- CARVEGF have enhanced in vivo potency in immunocompromised mouse models of metastatic ovarian and lung cancer
- 70VEGF cells target delivery of VEGF blockade within an orthotopic RCC model in immunocompromised mice
